Replies to post #625751 on NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

McKesson/HCA joint venture of the two TITANS along with their longstanding relations and high profile contacts especially in The New Era of Personalized Immuno Oncology re Cancer Moonshot, AmlflyBio/ Battelle Memorial will be 10X what
The Parker Cancer Institute has done since 2016 :https://en.wikipedia.org/wiki/Sean_Parker?wprov=sfla1

NWBO's DIRECT trial by Private Investigator

Colorectal Cancer Screening — Approach, Evidence, and Future Directions | NEJM Evidence https://t.co/NaO78prVh1

— Vivek Subbiah, MD (@VivekSubbiah) August 28, 2023

and his wife BOTH left the prominent MD Anderson Cancer Center (1 of 7 in Parker Cancer Institute) in the last year for big career moves to McKesson/HCA venture likely underscore the internal ruckus likely both faced at MD Anderson & even though collaboration thru 6 others via Parker Cancer Institute since 2016 was like rocket fuel propulsion, The McKesson/HCA setup is MANY MANY FOLD that of Parker Cancer Institute

So the couple can have a bigger audience with HUGE resources & much bigger universe by which to get their fulfillment!

BTW after uncovering what has transpired at Amazon's secretive Grand Challenge Group I strongly believe & urged DStock to establish a foothold into AMZN Grand Challenge as there is a CAPTIVE enterprising audience that will light a GOOD FIRE.
Evidently the group went about it incorrectly! and IMHO DStock will be IMPACTFUL!

DIFFERENT STROKES for DIFFERENT FOLKS

[dstock07734]

marzan,

Thanks. I am just a minnow swimming along with many whales.

One thing I feel really interesting is McKensson's unique expertise in using real world evidence to file for FDA approval.

A powerful, real-world evidence study designed by McKesson Specialty Health for its biopharma partner played a key role in the Food and Drug Administration’s (FDA) approval for first-line indication for a rare disease. Recently “Merkel Cell Carcinoma Observational Study for Historic Comparison” received the 2018 Clinical and Research Excellence (CARE) Award for Best in Health Economics and Outcomes Research, recognizing how data research supports true innovation in oncology care.

McKensson has Ontada and Aetion purely oriented for RWE (real world evidence). Dr. Vivek Subbiah is a big champion of using RWE for regulatory approval.

https://www.businesswire.com/news/home/20210519005219/en/

The longs here are worried about the trials that NWBO is planning to carry out will take another five years or longer. My speculation is that this won't happen. NWBO is going to use real world evidence for regulatory approval. That's what NWBO is going to do in the next stage. We will see pretty soon what "revolutionize cancer clinical research" means. Hopefully in a couple of months.